Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Healy, David
2006.
The Latest Mania: Selling Bipolar Disorder.
PLoS Medicine,
Vol. 3,
Issue. 4,
p.
e185.
Kreyenbuhl, Julie
Valenstein, Marcia
McCarthy, John F.
Ganoczy, Dara
and
Blow, Frederic C.
2006.
Long-term combination antipsychotic treatment in VA patients with schizophrenia.
Schizophrenia Research,
Vol. 84,
Issue. 1,
p.
90.
Mitchell, Alex J
and
Malone, Darren
2006.
Physical health and schizophrenia.
Current Opinion in Psychiatry,
Vol. 19,
Issue. 4,
p.
432.
Gilleard, C.
2006.
Risk factors for coronary heart disease in people with severe
mental illness.
British Journal of Psychiatry,
Vol. 189,
Issue. 3,
p.
285.
Healy, David
2006.
Neuroleptics and mortality: a 50-year cycle.
British Journal of Psychiatry,
Vol. 188,
Issue. 2,
p.
128.
Auquier, Pascal
Lançon, Christophe
Rouillon, Frédéric
Lader, Malcolm
and
Holmes, Catriona
2006.
Mortality in schizophrenia.
Pharmacoepidemiology and Drug Safety,
Vol. 15,
Issue. 12,
p.
873.
Bonetto, Chiara
Nosè, Michela
and
Barbui, Corrado
2006.
Generating psychotropic drug exposure data from computer-based medical records.
Computer Methods and Programs in Biomedicine,
Vol. 83,
Issue. 2,
p.
120.
2006.
Current awareness: Pharmacoepidemiology and drug safety.
Pharmacoepidemiology and Drug Safety,
Vol. 15,
Issue. 8,
Bär, Karl-Jürgen
Koschke, Mandy
Boettger, Michael Karl
Berger, Sandy
Kabisch, Alexander
Sauer, Heinrich
Voss, Andreas
and
Yeragani, Vikram K.
2007.
Acute psychosis leads to increased QT variability in patients suffering from schizophrenia.
Schizophrenia Research,
Vol. 95,
Issue. 1-3,
p.
115.
Seeman, Mary V
2007.
An Outcome Measure in Schizophrenia: Mortality.
The Canadian Journal of Psychiatry,
Vol. 52,
Issue. 1,
p.
55.
Tyrer, Peter
2007.
From the Editor's desk.
British Journal of Psychiatry,
Vol. 191,
Issue. 3,
p.
278.
Baker, John Anthony
Lovell, Karina
and
Harris, Neil
2007.
Mental health professionals' psychotropic pro re nata (p.r.n.) medication practices in acute inpatient mental health care: a qualitative study.
General Hospital Psychiatry,
Vol. 29,
Issue. 2,
p.
163.
Correll, Christoph U.
Frederickson, Anne M.
Kane, John M.
and
Manu, Peter
2007.
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?.
Schizophrenia Research,
Vol. 89,
Issue. 1-3,
p.
91.
Leuci, E.
Manenti, L.
and
Maggini, C.
2007.
Anti-phospholipid antibodies, neuroleptic treatment and cardiovascular morbidity.
British Journal of Psychiatry,
Vol. 190,
Issue. 1,
p.
81.
Nahshoni, Eitan
Spitzer, Sara
Berant, Michael
Shoval, Gal
Zalsman, Gil
and
Weizman, Abraham
2007.
QT Interval and Dispersion in Very Young Children Treated with Antipsychotic Drugs: A Retrospective Chart Review.
Journal of Child and Adolescent Psychopharmacology,
Vol. 17,
Issue. 2,
p.
187.
Ran, Mao-Sheng
Chen, Eric Yu-Hai
Conwell, Yeates
Chan, Cecilia Lai-Wan
Yip, Paul S. F.
Xiang, Meng-Ze
and
Caine, Eric D.
2007.
Mortality in people with schizophrenia in rural
China.
British Journal of Psychiatry,
Vol. 190,
Issue. 3,
p.
237.
Honer, William G
Thornton, Allen E
Sherwood, Megan
MacEwan, G ??William
Ehmann, Tom S
Williams, Richard
Kopala, Lili C
Procyshyn, Ric
and
Barr, Alasdair M
2007.
Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia.
CNS Drugs,
Vol. 21,
Issue. 9,
p.
699.
Barbui, Corrado
Biancosino, Bruno
Esposito, Eleonora
Marmai, Luciana
Donà, Silvia
and
Grassi, Luigi
2007.
Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study.
International Clinical Psychopharmacology,
Vol. 22,
Issue. 4,
p.
221.
Healy, David
2007.
The engineers of human souls & academia.
Epidemiologia e Psichiatria Sociale,
Vol. 16,
Issue. 3,
p.
205.
Suzuki, Takefumi
Uchida, Hiroyuki
Watanabe, Koichiro
Nakajima, Shinichiro
Nomura, Kensuke
Takeuchi, Hiroyoshi
Tanabe, Akira
Yagi, Gohei
and
Kashima, Haruo
2008.
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open‐label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
Human Psychopharmacology: Clinical and Experimental,
Vol. 23,
Issue. 6,
p.
455.
eLetters
No eLetters have been published for this article.